Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IDEAYA Biosciences, Inc.IDYA · Entity 4069 | Director | June 16, 2026 | June 18, 2026 |
| INOVIO PHARMACEUTICALS, INC.INO · Entity 6589 | Director | May 20, 2026 | May 21, 2026 |
| IOVANCE BIOTHERAPEUTICS, INC.IOVA · Entity 2090 | Director | June 13, 2025 | June 17, 2025 |
| Tarsus Pharmaceuticals, Inc.TARS · Entity 1836 | Director | September 15, 2026 | September 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IDEAYA Biosciences, Inc.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.57 · Expires 2036-06-16 | Direct | 20,000 |
Reported balance
After 2026-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 20,000 · Balance 20,000 F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date.
INOVIO PHARMACEUTICALS, INC.
Report date May 20, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.23 · Expires 2036-05-20 | Direct | 41,800 |
Reported balance
After 2026-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 41,800 · Balance 41,800 F1: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. F2: Options to vest 100% on May 20, 2027. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 34,200 |
Reported balance
After 2026-05-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-20 · Grant · Acquired 34,200 · Balance 34,200 F3: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027. F1: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. |
Filing footnotes · ownership attribution and instrument terms
F1: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy.
F2: Options to vest 100% on May 20, 2027.
F3: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027.
IOVANCE BIOTHERAPEUTICS, INC.
Report date June 13, 2025 · Filed June 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 67,546 |
Reported balance
After 2025-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-13 · Grant · Acquired 67,546 · Balance 67,546 F1: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended). F2: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended).
F2: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date.
Tarsus Pharmaceuticals, Inc.
Report date September 15, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,956 |
Reported balance
After 2026-09-15 transaction · row 1
1 source rowRow 1 · 2026-09-15 · Exercise / conversion · Acquired 302 · Balance 16,956 F1: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 907 |
Reported balance
After 2026-09-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-15 · Exercise / conversion · Disposed 302 · Balance 907 F2: Each RSU represents a contingent right to receive one share of the Company's common stock. F3: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
F2: Each RSU represents a contingent right to receive one share of the Company's common stock.
F3: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service.
Past disclosures · reporting ended (6)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALDER BIOPHARMACEUTICALS INC
Report date October 22, 2019 · Filed October 24, 2019
Section 16 reporting ended · disclosed 2019-10-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-10-22 transaction · row 1
1 source rowRow 1 · 2019-10-22 · Other · Disposed 5,000 · Balance 0 F1: On September 16, 2019, the Reporting Person entered into a Tender and Support (the "Support Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC, Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser") and certain other securityholders of Issuer, pursuant to which the Reporting Person agreed to tender all shares of the Issuer's Common Stock, Class A-1 Convertible Preferred Stock or shares of Common Stock underlying stock options, as the case may be, held by Reporting Person to Purchaser (the "Tender Offer"). On October 22, 2019, Purchaser accepted the Tender Offer. F2: The Reporting Person will also receive one non-transferable contingent value right for each share held, which will entitle them to receive up to an additional $2.00 per share upon achievement of a milestone. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.75 · Expires 2027-04-10 | Direct | 0 |
Reported balance
After 2019-10-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-10-22 · Disposition to issuer · Disposed 30,000 · Balance 0 F3: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F4: The shares subject to this option shall vest and become exercisable at a rate of one-third of the shares underlying the option on the one-year anniversary of March 31, 2017 (the "Vesting Commencement Date"), one-third of the shares underlying the option on the two-year anniversary of the Vesting Commencement Date and one-third of the shares underlying the option on the three-year anniversary of the Vesting Commencement Date, for so long as the Reporting Person provides continuous service to the Issuer, such that the total shares shall be fully vested on the three-year anniversary of the Vesting Commencement Date. F5: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive up to $0.25 per share upon achievement of a milestone. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.90 · Expires 2027-05-23 | Direct | 0 |
Reported balance
After 2019-10-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-10-22 · Disposition to issuer · Disposed 15,000 · Balance 0 F3: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F6: The shares subject to this option shall fully vest and become exercisable on the date of the 2018 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof. F7: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.50 · Expires 2028-05-22 | Direct | 0 |
Reported balance
After 2019-10-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-10-22 · Disposition to issuer · Disposed 15,000 · Balance 0 F3: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F7: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F8: The shares subject to this option shall fully vest and become exercisable on the date of the 2019 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.01 · Expires 2029-05-22 | Direct | 0 |
Reported balance
After 2019-10-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-10-22 · Disposition to issuer · Disposed 22,500 · Balance 0 F3: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F7: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F9: The shares subject to this option shall fully vest and become exercisable on the date of the 2020 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 16, 2019, the Reporting Person entered into a Tender and Support (the "Support Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC, Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser") and certain other securityholders of Issuer, pursuant to which the Reporting Person agreed to tender all shares of the Issuer's Common Stock, Class A-1 Convertible Preferred Stock or shares of Common Stock underlying stock options, as the case may be, held by Reporting Person to Purchaser (the "Tender Offer"). On October 22, 2019, Purchaser accepted the Tender Offer.
F2: The Reporting Person will also receive one non-transferable contingent value right for each share held, which will entitle them to receive up to an additional $2.00 per share upon achievement of a milestone.
F3: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck.
F4: The shares subject to this option shall vest and become exercisable at a rate of one-third of the shares underlying the option on the one-year anniversary of March 31, 2017 (the "Vesting Commencement Date"), one-third of the shares underlying the option on the two-year anniversary of the Vesting Commencement Date and one-third of the shares underlying the option on the three-year anniversary of the Vesting Commencement Date, for so long as the Reporting Person provides continuous service to the Issuer, such that the total shares shall be fully vested on the three-year anniversary of the Vesting Commencement Date.
F5: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive up to $0.25 per share upon achievement of a milestone.
F6: The shares subject to this option shall fully vest and become exercisable on the date of the 2018 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof.
F7: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone.
F8: The shares subject to this option shall fully vest and become exercisable on the date of the 2019 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof.
F9: The shares subject to this option shall fully vest and become exercisable on the date of the 2020 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date.
ARATANA THERAPEUTICS, INC.
Report date July 18, 2019 · Filed July 18, 2019
Section 16 reporting ended · disclosed 2019-07-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-07-18 transaction · row 1
1 source rowRow 1 · 2019-07-18 · Disposition to issuer · Disposed 18,000 · Balance 0 F1: On July 18, 2019, pursuant to that certain Agreement and Plan of Merger dated April 26, 2019 (the "Merger Agreement") among Aratana Therapeutics, Inc. (the "Company"), Elanco Animal Health Incorporated ("Elanco") and Elanco Athens, Inc., a Delaware corporation and a direct wholly owned subsidiary of Elanco ("Elanco Athens"), Elanco Athens merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Elanco. Pursuant to the Merger Agreement, each outstanding share of Company common stock (other than certain excluded shares as described in the Merger Agreement) was converted into the right to receive (A) 0.1481 validly issued, fully paid and non-assessable shares of Elanco common stock (the "Stock Consideration"), having a market value of $4.91 on the effective date of the Merger, and (B) one contingent value right, which represents the contractual right to receive a contingent cash (continued in footnote 2) F2: (continued from footnote 1) payment of $0.25 per share of Company common stock if a specified milestone is achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated July 18, 2019, by and among Elanco, Broadridge Corporate Issuer Solutions, Inc., and UMB Bank, National Association (together with the Stock Consideration, the "Merger Consideration"). F3: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of all outstanding unvested Company restricted stock awards was accelerated in full and each such restricted stock award was cancelled and terminated as of the effective time of the Merger. Each holder of a Company restricted stock award received the right to the Merger Consideration due with respect to the shares of Company common stock received in exchange for such accelerated restricted stock awards. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.04 | Direct | 0 |
Reported balance
After 2019-07-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-07-18 · Disposition to issuer · Disposed 13,237 · Balance 0 F4: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.03 | Direct | 0 |
Reported balance
After 2019-07-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-07-18 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.27 | Direct | 0 |
Reported balance
After 2019-07-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-07-18 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.12 | Direct | 0 |
Reported balance
After 2019-07-18 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-07-18 · Disposition to issuer · Disposed 7,500 · Balance 0 F4: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.84 | Direct | 0 |
Reported balance
After 2019-07-18 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-07-18 · Disposition to issuer · Disposed 7,500 · Balance 0 F4: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.36 | Direct | 0 |
Reported balance
After 2019-07-18 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-07-18 · Disposition to issuer · Disposed 7,500 · Balance 0 F4: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.80 | Direct | 0 |
Reported balance
After 2019-07-18 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-07-18 · Disposition to issuer · Disposed 7,500 · Balance 0 F4: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 18, 2019, pursuant to that certain Agreement and Plan of Merger dated April 26, 2019 (the "Merger Agreement") among Aratana Therapeutics, Inc. (the "Company"), Elanco Animal Health Incorporated ("Elanco") and Elanco Athens, Inc., a Delaware corporation and a direct wholly owned subsidiary of Elanco ("Elanco Athens"), Elanco Athens merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Elanco. Pursuant to the Merger Agreement, each outstanding share of Company common stock (other than certain excluded shares as described in the Merger Agreement) was converted into the right to receive (A) 0.1481 validly issued, fully paid and non-assessable shares of Elanco common stock (the "Stock Consideration"), having a market value of $4.91 on the effective date of the Merger, and (B) one contingent value right, which represents the contractual right to receive a contingent cash (continued in footnote 2)
F2: (continued from footnote 1) payment of $0.25 per share of Company common stock if a specified milestone is achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated July 18, 2019, by and among Elanco, Broadridge Corporate Issuer Solutions, Inc., and UMB Bank, National Association (together with the Stock Consideration, the "Merger Consideration").
F3: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of all outstanding unvested Company restricted stock awards was accelerated in full and each such restricted stock award was cancelled and terminated as of the effective time of the Merger. Each holder of a Company restricted stock award received the right to the Merger Consideration due with respect to the shares of Company common stock received in exchange for such accelerated restricted stock awards.
F4: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares.
Global Blood Therapeutics, Inc.
Report date October 05, 2022 · Filed October 06, 2022
Section 16 reporting ended · disclosed 2022-10-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 1
1 source rowRow 1 · 2022-10-05 · Disposition to issuer · Disposed 11,437 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-10-05 · Disposition to issuer · Disposed 3,600 · Balance 0 F3: Each restricted stock unit of the Issuer ("RSU") represented a contingent right to receive one share of Common Stock. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.55 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-10-05 · Disposition to issuer · Disposed 30,000 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.25 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-10-05 · Disposition to issuer · Disposed 15,000 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.30 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-10-05 · Disposition to issuer · Disposed 7,500 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.75 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-10-05 · Disposition to issuer · Disposed 5,247 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.09 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-10-05 · Disposition to issuer · Disposed 5,600 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.30 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-10-05 · Disposition to issuer · Disposed 5,600 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.
F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
F3: Each restricted stock unit of the Issuer ("RSU") represented a contingent right to receive one share of Common Stock.
F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.
F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
MEDIVATION, INC.
Report date September 28, 2016 · Filed September 30, 2016
Section 16 reporting ended · disclosed 2016-09-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 1
1 source rowRow 1 · 2016-09-28 · Other · Disposed 32,742 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal. F2: Includes 2,972 unvested shares subject to a restricted stock award. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.36 · Expires 2023-04-30 | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2016-09-28 · Disposition to issuer · Disposed 30,000 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.60 · Expires 2023-06-28 | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-09-28 · Disposition to issuer · Disposed 12,232 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.89 · Expires 2024-06-27 | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2016-09-28 · Disposition to issuer · Disposed 9,584 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.45 · Expires 2025-06-16 | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2016-09-28 · Disposition to issuer · Disposed 6,284 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.89 · Expires 2026-06-22 | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2016-09-28 · Disposition to issuer · Disposed 6,228 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal.
F2: Includes 2,972 unvested shares subject to a restricted stock award.
F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
MyoKardia, Inc.
Report date November 17, 2020 · Filed November 20, 2020
Section 16 reporting ended · disclosed 2020-11-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-11-17 transaction · row 1
1 source rowRow 1 · 2020-11-17 · Other · Disposed 5,508 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.35 | Direct | 0 |
Reported balance
After 2020-11-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-11-17 · Disposition to issuer · Disposed 22,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00 | Direct | 0 |
Reported balance
After 2020-11-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-11-17 · Disposition to issuer · Disposed 11,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.85 | Direct | 0 |
Reported balance
After 2020-11-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-11-17 · Disposition to issuer · Disposed 11,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.77 | Direct | 0 |
Reported balance
After 2020-11-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-11-17 · Disposition to issuer · Disposed 6,600 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.27 | Direct | 0 |
Reported balance
After 2020-11-17 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-11-17 · Disposition to issuer · Disposed 3,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price.
F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
ST JUDE MEDICAL, LLC
Report date January 04, 2017 · Filed January 06, 2017
Section 16 reporting ended · disclosed 2017-01-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 1
1 source rowRow 1 · 2017-01-04 · Disposition to issuer · Disposed 30,240 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.45 · Expires 2017-05-08 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-01-04 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.45 · Expires 2017-05-08 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-01-04 · Disposition to issuer · Disposed 2,250 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.15 · Expires 2018-05-07 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-01-04 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.15 · Expires 2018-05-07 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-01-04 · Disposition to issuer · Disposed 600 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.17 · Expires 2019-05-12 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-01-04 · Disposition to issuer · Disposed 9,700 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.51 · Expires 2020-05-03 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2017-01-04 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.51 · Expires 2020-05-03 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2017-01-04 · Disposition to issuer · Disposed 5,400 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock.
F2: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 22, 2019 Filed Oct 24, 2019 23:05 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $15.50 | $0.00 |
DisclosureSEC source: 0001209191-19-053918 · doc4.xml · derivative · entry 4 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2028-05-22 F3 · date: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F7 · derivative.exercise_date: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F8 · derivative.exercise_date: The shares subject to this option shall fully vest and become exercisable on the date of the 2019 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 23:05 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $16.90 | $0.00 |
DisclosureSEC source: 0001209191-19-053918 · doc4.xml · derivative · entry 3 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2027-05-23 F3 · date: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F6 · derivative.exercise_date: The shares subject to this option shall fully vest and become exercisable on the date of the 2018 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof. F7 · derivative.exercise_date: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 23:05 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Disposition to issuerStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $19.75 | $0.00 |
DisclosureSEC source: 0001209191-19-053918 · doc4.xml · derivative · entry 2 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2027-04-10 F3 · date: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F4 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of one-third of the shares underlying the option on the one-year anniversary of March 31, 2017 (the "Vesting Commencement Date"), one-third of the shares underlying the option on the two-year anniversary of the Vesting Commencement Date and one-third of the shares underlying the option on the three-year anniversary of the Vesting Commencement Date, for so long as the Reporting Person provides continuous service to the Issuer, such that the total shares shall be fully vested on the three-year anniversary of the Vesting Commencement Date. F5 · derivative.exercise_date: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive up to $0.25 per share upon achievement of a milestone. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 23:05 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | OtherCommon Stock | 5,000 | $18.00 | $90,000.00 |
DisclosureSEC source: 0001209191-19-053918 · doc4.xml · nonDerivative · entry 1 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · date: On September 16, 2019, the Reporting Person entered into a Tender and Support (the "Support Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC, Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser") and certain other securityholders of Issuer, pursuant to which the Reporting Person agreed to tender all shares of the Issuer's Common Stock, Class A-1 Convertible Preferred Stock or shares of Common Stock underlying stock options, as the case may be, held by Reporting Person to Purchaser (the "Tender Offer"). On October 22, 2019, Purchaser accepted the Tender Offer. F2 · price: The Reporting Person will also receive one non-transferable contingent value right for each share held, which will entitle them to receive up to an additional $2.00 per share upon achievement of a milestone. Read SEC document |
| July 18, 2019 Filed Jul 18, 2019 23:56 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,500 | Not disclosed Strike: $4.80 | Not disclosed |
DisclosureSEC source: 0001209191-19-042727 · doc4.xml · derivative · entry 8 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed F4 · price: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares. F4 · derivative.exercise_date: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares. F4 · derivative.expiration_date: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares. Read SEC document |
| July 18, 2019 Filed Jul 18, 2019 23:56 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,500 | Not disclosed Strike: $4.36 | Not disclosed |
DisclosureSEC source: 0001209191-19-042727 · doc4.xml · derivative · entry 7 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed F4 · price: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares. F4 · derivative.exercise_date: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares. F4 · derivative.expiration_date: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares. Read SEC document |
| July 18, 2019 Filed Jul 18, 2019 23:56 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,500 | Not disclosed Strike: $6.84 | Not disclosed |
DisclosureSEC source: 0001209191-19-042727 · doc4.xml · derivative · entry 6 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed F4 · price: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares. F4 · derivative.exercise_date: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares. F4 · derivative.expiration_date: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares. Read SEC document |
| July 18, 2019 Filed Jul 18, 2019 23:56 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,500 | Not disclosed Strike: $6.12 | Not disclosed |
DisclosureSEC source: 0001209191-19-042727 · doc4.xml · derivative · entry 5 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed F4 · price: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares. F4 · derivative.exercise_date: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares. F4 · derivative.expiration_date: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares. Read SEC document |
| July 18, 2019 Filed Jul 18, 2019 23:56 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $14.27 | Not disclosed |
DisclosureSEC source: 0001209191-19-042727 · doc4.xml · derivative · entry 4 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F4 · price: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares. F4 · derivative.exercise_date: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares. F4 · derivative.expiration_date: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares. Read SEC document |
| July 18, 2019 Filed Jul 18, 2019 23:56 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $15.03 | Not disclosed |
DisclosureSEC source: 0001209191-19-042727 · doc4.xml · derivative · entry 3 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F4 · price: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares. F4 · derivative.exercise_date: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares. F4 · derivative.expiration_date: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares. Read SEC document |
| July 18, 2019 Filed Jul 18, 2019 23:56 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | Disposition to issuerStock Option (Right to Buy) · Derivative | 13,237 | Not disclosed Strike: $28.04 | Not disclosed |
DisclosureSEC source: 0001209191-19-042727 · doc4.xml · derivative · entry 2 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,237 shares Expires not disclosed F4 · price: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares. F4 · derivative.exercise_date: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares. F4 · derivative.expiration_date: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares. Read SEC document |
| July 18, 2019 Filed Jul 18, 2019 23:56 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | Disposition to issuerCommon Stock | 18,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-042727 · doc4.xml · nonDerivative · entry 1 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: On July 18, 2019, pursuant to that certain Agreement and Plan of Merger dated April 26, 2019 (the "Merger Agreement") among Aratana Therapeutics, Inc. (the "Company"), Elanco Animal Health Incorporated ("Elanco") and Elanco Athens, Inc., a Delaware corporation and a direct wholly owned subsidiary of Elanco ("Elanco Athens"), Elanco Athens merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Elanco. Pursuant to the Merger Agreement, each outstanding share of Company common stock (other than certain excluded shares as described in the Merger Agreement) was converted into the right to receive (A) 0.1481 validly issued, fully paid and non-assessable shares of Elanco common stock (the "Stock Consideration"), having a market value of $4.91 on the effective date of the Merger, and (B) one contingent value right, which represents the contractual right to receive a contingent cash (continued in footnote 2) F2 · shares: (continued from footnote 1) payment of $0.25 per share of Company common stock if a specified milestone is achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated July 18, 2019, by and among Elanco, Broadridge Corporate Issuer Solutions, Inc., and UMB Bank, National Association (together with the Stock Consideration, the "Merger Consideration"). F3 · shares: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of all outstanding unvested Company restricted stock awards was accelerated in full and each such restricted stock award was cancelled and terminated as of the effective time of the Merger. Each holder of a Company restricted stock award received the right to the Merger Consideration due with respect to the shares of Company common stock received in exchange for such accelerated restricted stock awards. F1 · price: On July 18, 2019, pursuant to that certain Agreement and Plan of Merger dated April 26, 2019 (the "Merger Agreement") among Aratana Therapeutics, Inc. (the "Company"), Elanco Animal Health Incorporated ("Elanco") and Elanco Athens, Inc., a Delaware corporation and a direct wholly owned subsidiary of Elanco ("Elanco Athens"), Elanco Athens merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Elanco. Pursuant to the Merger Agreement, each outstanding share of Company common stock (other than certain excluded shares as described in the Merger Agreement) was converted into the right to receive (A) 0.1481 validly issued, fully paid and non-assessable shares of Elanco common stock (the "Stock Consideration"), having a market value of $4.91 on the effective date of the Merger, and (B) one contingent value right, which represents the contractual right to receive a contingent cash (continued in footnote 2) F2 · price: (continued from footnote 1) payment of $0.25 per share of Company common stock if a specified milestone is achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated July 18, 2019, by and among Elanco, Broadridge Corporate Issuer Solutions, Inc., and UMB Bank, National Association (together with the Stock Consideration, the "Merger Consideration"). Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 20:01 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantRestricted Stock Units · Derivative | 4,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-017612 · doc4.xml · derivative · entry 2 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,800 Underlying: Common Stock · 4,800 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 18, 2020, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 18, 2020, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 18, 2020, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 20:01 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $56.30 | $0.00 |
DisclosureSEC source: 0000899243-19-017612 · doc4.xml · derivative · entry 1 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-06-17 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 18, 2019, for 11 months and the remaining 1/12th on the earlier of (i) June 18, 2020 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 22:59 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantRestricted Stock Units · Derivative | 2,300 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-017230 · doc4.xml · derivative · entry 2 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,300 Underlying: Common Stock · 2,300 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 22:59 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantStock Option (Right to Buy) · Derivative | 6,600 | $0.00 Strike: $47.17 | $0.00 |
DisclosureSEC source: 0000899243-19-017230 · doc4.xml · derivative · entry 1 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,600 Underlying: Common Stock · 6,600 shares Expires 2029-06-12 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 12 equal monthly installments with the first installment on July 13, 2019, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 22:06 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001209191-19-035642 · doc4.xml · derivative · entry 2 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-06-05 F1 · derivative.exercise_date: Vests on the earlier of (i) the first anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's next annual meeting of stockholders following the date of grant, subject to continued service as a member of the Board of Directors of the Issuer through such vesting date. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 22:06 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-035642 · doc4.xml · nonDerivative · entry 1 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Read SEC document |
| May 23, 2019 Filed May 28, 2019 22:17 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $11.01 | $0.00 |
DisclosureSEC source: 0001209191-19-033081 · doc4.xml · derivative · entry 1 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2029-05-22 F1 · derivative.exercise_date: The shares subject to this option shall fully vest and become exercisable on the date of the 2020 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. Read SEC document |
| May 11, 2019 Filed May 13, 2019 20:02 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 8,170 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-19-000041 · wf-form4_155777772830070.xml · derivative · entry 2 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,170 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested with respect to 100% of the shares on May 11, 2019. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested with respect to 100% of the shares on May 11, 2019. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested with respect to 100% of the shares on May 11, 2019. Read SEC document |
| May 11, 2019 Filed May 13, 2019 20:02 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 8,170 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-19-000041 · wf-form4_155777772830070.xml · nonDerivative · entry 1 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,260 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested with respect to 100% of the shares on May 11, 2019. Read SEC document |
| May 08, 2019 Filed May 9, 2019 22:03 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 8,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-19-000032 · wf-form4_155743940193667.xml · derivative · entry 2 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,013 Underlying: Common Stock · 8,013 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 8, 2020. F1 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 8, 2020. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 8, 2020. Read SEC document |
| May 08, 2019 Filed May 9, 2019 22:03 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Options · Derivative | 12,500 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0001055726-19-000032 · wf-form4_155743940193667.xml · derivative · entry 1 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2029-05-08 F1 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F2 · derivative.exercise_date: Options to vest with respect to 100% of the shares on May 8, 2020. Read SEC document |
| December 05, 2018 Filed Dec 6, 2018 22:15 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 4,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-18-000048 · wf-form4_154413452889176.xml · derivative · entry 2 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,180 Underlying: Common Stock · 4,090 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,270 restricted stock units is as follows: 4,090 shares vested on December 5, 2018; 4,090 shares will vest on December 5, 2019; 4,090 shares will vest on December 5, 2020. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,270 restricted stock units is as follows: 4,090 shares vested on December 5, 2018; 4,090 shares will vest on December 5, 2019; 4,090 shares will vest on December 5, 2020. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,270 restricted stock units is as follows: 4,090 shares vested on December 5, 2018; 4,090 shares will vest on December 5, 2019; 4,090 shares will vest on December 5, 2020. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,270 restricted stock units is as follows: 4,090 shares vested on December 5, 2018; 4,090 shares will vest on December 5, 2019; 4,090 shares will vest on December 5, 2020. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| December 05, 2018 Filed Dec 6, 2018 22:15 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 4,090 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-18-000048 · wf-form4_154413452889176.xml · nonDerivative · entry 1 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,270 restricted stock units is as follows: 4,090 shares vested on December 5, 2018; 4,090 shares will vest on December 5, 2019; 4,090 shares will vest on December 5, 2020. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| July 27, 2018 Filed Jul 30, 2018 21:58 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $4.36 | $0.00 |
DisclosureSEC source: 0001209191-18-044456 · doc4.xml · derivative · entry 2 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2028-07-26 F1 · derivative.exercise_date: Vests on the earlier of (i) the first anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's next annual meeting of stockholders following the date of grant, subject to continued service as a member of the Board of Directors of the Issuer through such vesting date. Read SEC document |
| July 27, 2018 Filed Jul 30, 2018 21:58 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-044456 · doc4.xml · nonDerivative · entry 1 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 22:21 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $42.25 | $0.00 |
DisclosureSEC source: 0000899243-18-017767 · doc4.xml · derivative · entry 1 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-19 F1 · derivative.exercise_date: The shares vest and become exercisable in 12 equal monthly installments, with the first installment on July 20, 2018, subject to the recipient's continued service on the Issuer's Board of Directors. This option is subject to accelerated vesting upon a change of control of the Issuer. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 20:06 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $48.85 | $0.00 |
DisclosureSEC source: 0000899243-18-016594 · doc4.xml · derivative · entry 1 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2028-06-11 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 12 equal monthly installments with the first installment on July 12, 2018, such that this option is fully exercisable on June 12, 2019. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document |
| May 23, 2018 Filed May 25, 2018 21:21 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $15.50 | $0.00 |
DisclosureSEC source: 0001209191-18-033605 · doc4.xml · derivative · entry 1 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-05-22 F1 · derivative.exercise_date: The shares subject to this option shall fully vest and become exercisable on the date of the 2019 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. Read SEC document |
| May 11, 2018 Filed May 14, 2018 22:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 8,170 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-18-000031 · wf-form4_152633566960335.xml · derivative · entry 2 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,170 Underlying: Common Stock · 8,170 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 11, 2019. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 11, 2019. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 11, 2019. Read SEC document |
| May 11, 2018 Filed May 14, 2018 22:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 12,500 | $0.00 Strike: $4.56 | $0.00 |
DisclosureSEC source: 0001055726-18-000031 · wf-form4_152633566960335.xml · derivative · entry 1 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-05-11 F1 · derivative.exercise_date: Options to vest 100% on May 11, 2019. Read SEC document |
| December 21, 2017 Filed Dec 22, 2017 23:40 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantEmployee Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $38.55 | $0.00 |
DisclosureSEC source: 0000899243-17-029484 · doc4.xml · derivative · entry 1 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-12-20 F1 · derivative.exercise_date: The shares vest and become exercisable in 36 equal monthly installments, with the first installment on January 21, 2018. This option is subject to accelerated vesting upon a change of control of the Issuer. Read SEC document |
| December 05, 2017 Filed Dec 6, 2017 19:07 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 12,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-17-000041 · wf-form4_151258721187591.xml · derivative · entry 2 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,270 Underlying: Common Stock · 12,270 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,270 restricted stock units is as follows: 4,090 shares will vest on December 5, 2018; 4,090 shares will vest on December 5, 2019; 4,090 shares will vest on December 5, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,270 restricted stock units is as follows: 4,090 shares will vest on December 5, 2018; 4,090 shares will vest on December 5, 2019; 4,090 shares will vest on December 5, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,270 restricted stock units is as follows: 4,090 shares will vest on December 5, 2018; 4,090 shares will vest on December 5, 2019; 4,090 shares will vest on December 5, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| December 05, 2017 Filed Dec 6, 2017 19:07 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 20,000 | $4.38 Strike: $4.38 | $87,600.00 |
DisclosureSEC source: 0001055726-17-000041 · wf-form4_151258721187591.xml · derivative · entry 1 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-12-05 F1 · derivative.exercise_date: The vesting schedule for the 20,000 options is as follows: 5,000 shares vested on December 5, 2017; 5,000 shares will vest on December 5, 2018; 5,000 shares will vest on December 5, 2019; 5,000 shares will vest on December 5, 2020. Read SEC document |
| August 14, 2017 Filed Aug 16, 2017 20:33 UTC | MyoKardia, Inc. MYOK · Entity 145206 | PurchaseCommon Stock | 1,408 | $35.50 | $49,984.00 |
DisclosureSEC source: 0000899243-17-020486 · doc4.xml · nonDerivative · entry 1 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,408 Read SEC document |
| July 18, 2017 Filed Jul 18, 2017 23:52 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | PurchaseCommon Stock | 5,000 | $10.00 | $50,000.00 |
DisclosureSEC source: 0001209191-17-045607 · doc4.xml · nonDerivative · entry 1 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 21:43 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $6.84 | $0.00 |
DisclosureSEC source: 0001209191-17-041744 · doc4.xml · derivative · entry 2 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2027-06-20 F1 · derivative.exercise_date: Vests on the earlier of (i) the first anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's next annual meeting of stockholders following the date of grant, subject to continued service as a member of the Board of Directors of the Issuer through such vesting date. Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 21:43 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-041744 · doc4.xml · nonDerivative · entry 1 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 20:13 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0000899243-17-016562 · doc4.xml · derivative · entry 1 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2027-06-13 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 12 equal monthly installments with the first installment on July 14, 2017, such that this option is fully exercisable on June 14, 2018. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the issuer's 2015 Stock Option and Incentive Plan). Read SEC document |
| May 24, 2017 Filed May 26, 2017 22:12 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $16.90 | $0.00 |
DisclosureSEC source: 0001209191-17-036004 · doc4.xml · derivative · entry 1 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-05-23 F1 · derivative.exercise_date: The shares subject to this option shall fully vest and become exercisable on the date of the 2018 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. Read SEC document |
| April 11, 2017 Filed Apr 13, 2017 22:10 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $19.75 | $0.00 |
DisclosureSEC source: 0001209191-17-026908 · doc4.xml · derivative · entry 1 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-04-10 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of one-third of the shares underlying the option on the one-year anniversary of March 31, 2017 (the "Vesting Commencement Date"), one-third of the shares underlying the option on the two-year anniversary of the Vesting Commencement Date and one-third of the shares underlying the option on the three-year anniversary of the Vesting Commencement Date, for so long as the Reporting Person provides continuous service to the Issuer, such that the total shares shall be fully vested on the three-year anniversary of the Vesting Commencement Date. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 22:57 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $14.35 | $0.00 |
DisclosureSEC source: 0000899243-17-008075 · doc4.xml · derivative · entry 1 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2027-03-14 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments with the first installment on April 15, 2017, such that this option is fully exercisable on March 15, 2021. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the issuer's 2015 Stock Option and Incentive Plan). Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:26 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerStock Options (Right to Buy) · Derivative | 5,400 | Not disclosed Strike: $38.51 | Not disclosed |
DisclosureSEC source: 0001179110-17-000598 · edgar.xml · derivative · entry 8 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,400 shares Expires 2020-05-03 F2 · price: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:26 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerStock Options (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $38.51 | Not disclosed |
DisclosureSEC source: 0001179110-17-000598 · edgar.xml · derivative · entry 7 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2020-05-03 F2 · price: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:26 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerStock Options (Right to Buy) · Derivative | 9,700 | Not disclosed Strike: $52.17 | Not disclosed |
DisclosureSEC source: 0001179110-17-000598 · edgar.xml · derivative · entry 6 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,700 shares Expires 2019-05-12 F2 · price: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:26 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerStock Options (Right to Buy) · Derivative | 600 | Not disclosed Strike: $37.15 | Not disclosed |
DisclosureSEC source: 0001179110-17-000598 · edgar.xml · derivative · entry 5 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 600 shares Expires 2018-05-07 F2 · price: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:26 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerStock Options (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $37.15 | Not disclosed |
DisclosureSEC source: 0001179110-17-000598 · edgar.xml · derivative · entry 4 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2018-05-07 F2 · price: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:26 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerStock Options (Right to Buy) · Derivative | 2,250 | Not disclosed Strike: $36.45 | Not disclosed |
DisclosureSEC source: 0001179110-17-000598 · edgar.xml · derivative · entry 3 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,250 shares Expires 2017-05-08 F2 · price: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:26 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerStock Options (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $36.45 | Not disclosed |
DisclosureSEC source: 0001179110-17-000598 · edgar.xml · derivative · entry 2 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2017-05-08 F2 · price: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.